Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Cerilliant
Mallinckrodt
Queensland Health
Julphar
QuintilesIMS
Deloitte
UBS

Generated: December 12, 2018

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bimatoprost and what is the scope of bimatoprost patent protection?

Bimatoprost is the generic ingredient in three branded drugs marketed by Apotex Inc, Hi-tech Pharma Co, Lupin Ltd, Sandoz Inc, Allergan, and Hi-tech Pharmacal, and is included in ten NDAs. There are twenty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has sixty-five patent family members in twenty-one countries.

There are twelve drug master file entries for bimatoprost. Six suppliers are listed for this compound. There are three tentative approvals for this compound.

Pharmacology for bimatoprost
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for bimatoprost
Synonyms for bimatoprost
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide
(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid
206B001
267244-98-4
5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AB0015029
ABP000616
AC1NSJUW
AGN 192024
AGN-192024
AK173142
AKOS015995566
AM84507
AN-5283
AQOKCDNYWBIDND-FTOWTWDKSA-N
BDBM220120
Bimataprost [USAN:INN:BAN]
Bimatoprost (JAN/USAN/INN)
Bimatoprost (topical, alopecia)
Bimatoprost [USAN:INN:BAN]
Bimatoprost/Lumigan
bimatoprostum
CHEBI:51230
CHEMBL1200963
CS-2085
D02724
D0Q2XF
DB00905
GTPL1958
HY-B0191
I06-1275
I06-1277
Latisse
Latisse (TN)
LP075849
LS-181817
Lumigan
Lumigan (TN)
M052
MLS006010039
MolPort-006-167-657
NCGC00181745-01
Prostamide
QXS94885MZ
RP17728
SCHEMBL24425
SMR000058996
SR-01000942224
SR-01000942224-1
UNII-QXS94885MZ
US9271961, Bimatoprost
ZINC4474405
Tentative approvals for BIMATOPROST
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up0.03SOLUTION; OPHTHALMIC
➤ Sign Up➤ Sign Up0.01%SOLUTION; OPHTHALMIC
➤ Sign Up➤ Sign Up0.01%SOLUTION;OPHTHALMIC

US Patents and Regulatory Information for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Hi-tech Pharma Co BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 203299-001 Nov 8, 2018 AT RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Sign Up ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Sign Up ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for bimatoprost

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00099 Netherlands ➤ Sign Up PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0033 France ➤ Sign Up PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
C/GB02/035 United Kingdom ➤ Sign Up PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Deloitte
Johnson and Johnson
Baxter
Cipla
Express Scripts
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.